NCT Number: NCT00197938
Lactic Acid in the Rectum and Life-Threatening Infection
Life-threatening infection impairs bloodflow to the gut, thereby causing less delivery of oxygen. This leads to increased formation of lactic acid.
The investigators hypothesize, that the more serious the condition, the higher the concentration of lactic acid will be, thus relating to the risk of multiple organ failure or death.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Dept. of Intensive Care 4131, Rigshospitalet, Copenhagen, Denmark
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Fluid resuscitated septic shock < 24 h.
Exclusion criteria
- Septic shock > 24 h.
- Pathology in the rectum.
- Bleeding per rectum.
- Limitation of therapy.
- Where informed consent from relatives cannot be obtained.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Herlev Hospital
Other
Registry information
Official study title
Does the Concentration of L-Lactate in the Rectum Correlate With Mortality and Morbidity in Patients With Septic Shock?
Important dates
- Study start
- 2005
- Study completion
- 2009
- First posted
- Sep 20, 2005
- Registry last updated
- Jun 9, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients
NCT06363149
Blood Coagulation Disorders, Critical Illness
Lucknow, Uttar Pradesh, India
View Trial DetailsContinuous Infusion Versus Intermittent Bolus Hydrocortisone in Septic Shock
NCT07695337
Infections, Inflammation
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsSerum Biomarkers to Predict Response to Angiotensin II in Septic Shock
NCT05824767
Infections, Inflammation
Albuquerque, New Mexico, United States
View Trial DetailsOutcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock
NCT07313670
Infections, Inflammation
Karachi, Sindh, Pakistan
View Trial Details